scholarly journals Cardiomyopathy, Proximal Myopathy, Camptocormia, and Novel Filamin C (FLNC) Variant: A Case Report

2021 ◽  
Vol 22 ◽  
Author(s):  
Sara Jasmin Hooshmand ◽  
Raghav Govindarajan ◽  
Brian P. Bostick
2017 ◽  
Vol 27 (1) ◽  
pp. 73-77 ◽  
Author(s):  
Fleur J.A. van den Bogaart ◽  
Kristl G. Claeys ◽  
Rudolf A. Kley ◽  
Benno Kusters ◽  
Simone Schrading ◽  
...  

Rheumatology ◽  
1988 ◽  
Vol 27 (1) ◽  
pp. 62-64 ◽  
Author(s):  
C. A. BOWMAN ◽  
W. J. JEFFCOATE ◽  
M. PATTRICK ◽  
M. DOHERTY

BMC Neurology ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Juanjuan Chen ◽  
Jun Wu ◽  
Chunxi Han ◽  
Yao Li ◽  
Yuzu Guo ◽  
...  

2007 ◽  
Vol 135 (3-4) ◽  
pp. 197-200
Author(s):  
Suad Catovic ◽  
Petar Otasevic

Danon disease, a rare glycogen storage disease, is a dominant X-linked disorder. It is due to mutation in gene for lysosome-associated membrane protein 2 (LAMP 2). The LAMP 2 gene is located on Xq24, and its mutation causes primary deficiency of LAMP 2 and myocyte hypertrophy by accumulations of vacuoles containing glycogen. Danon disease is clinically characterized by the triad of hypertrophic cardiomyopathy (HCM), proximal myopathy and mental retardation. Myopathy and mental retardation can be absent, and cardiomyopathy is usually hypertrophic. This is a case report of the patient with genetically confirmed Danon disease and mixed cardiomyopathy, but without myopathy and mental retardation. ECG showed typical Wolff-Parkinson-White (WPW) pattern while echocardiography demonstrated hypertrophy and dilatation of all cardiac chambers with impaired systolic and diastolic function. Male sex, early onset of symptoms, massive hypertrophy of the myocardium and ventricular preexcitation indicate a genetic basis for HCM. Therapeutic measures, except heart transplantation, do not improve prognosis substantially. Only an accurate diagnosis in patients with unexplained HCM helps in establishing of the appropriate treatment strategies and adequate genetic consultation. .


2021 ◽  
Author(s):  
Shahin Besharati ◽  
Zahra Abbaspourrad ◽  
Hossein Chiti ◽  
Negin Parsamanesh

The 2019 global Coronavirus syndrome pandemic (COVID-19) has entered more than two hundred countries around the world, involving <82 million persons and >1,800,000 deaths (until January, 1st 2021). We report on COVID-19 infection in the context of a Cushing's syndrome (CS) from Iran. A 36-year-old man with proximal myopathy, plethora, and striae with central obesity was evaluated for Cushing's syndrome. During the high dose dexamethasone test, the patient developed symptoms of cough, low-grade fever, and weakness then was admitted to the ICU with a diagnosis of COVID-19. Despite treatment according to national protocols for COVID-19, the patient unfortunately died. In this report, we intend to discuss the various aspects of Cushing's syndrome and severe COVID-19 infection.


Sign in / Sign up

Export Citation Format

Share Document